EVOK - Evoke Pharma under pressure on proposed public offering

Evoke Pharma (EVOK) dropped 5.1% in after-hours after it announced plans to offer and sell shares of its common stock in a firm commitment underwritten public offering; underwriters granted 45-day option to purchase an additional 15% of the shares.Actual size, terms of the offer have not yet been disclosed.Net proceeds to be used for general corporate purposes, including funding commercialization activities, research and development activities, clinical trial expenditures, and possible acquisition of new technologies or products.

For further details see:

Evoke Pharma under pressure on proposed public offering